Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Estimates By $0.49 EPS

Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49, FiscalAI reports. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics updated its FY 2026 guidance to 8.650-9.000 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Adjusted EBITDA reached $328.8 million and non-GAAP EPS was $2.28.
• 2026 guidance was raised: Halozyme now expects total revenue of $1.835 billion-$1.91 billion, royalty revenue of $1.22 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.28 billion, and non-GAAP EPS of $8.65-$9.00.
• ENHANZE product diversification accelerated: Royalties from newer launches—including OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT SC—increased approximately 80% sequentially, complementing continued growth from DARZALEX SC, VYVGART Hytrulo, and PHESGO.
• Strong partnership momentum expanded the long-term pipeline: Halozyme signed five collaboration and licensing agreements across the quarter and July, including deals with GSK, Incyte, Vertex, and Oruka, generating $35.5 million in upfront revenue and expanding ENHANZE into ADCs and nucleic-acid therapies.
• Litigation remains an important uncertainty: Halozyme is pursuing injunctions against Merck in roughly eight countries and plans to appeal four U.S. patent-review decisions, although management expressed strong confidence it will ultimately prevail.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $2.17 on Thursday, hitting $85.76. 2,679,037 shares of the company were exchanged, compared to its average volume of 1,643,316. The company’s 50 day moving average price is $75.74 and its two-hundred day moving average price is $71.25. The firm has a market capitalization of $10.17 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 0.35 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics has a one year low of $61.22 and a one year high of $86.00.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Morgan Stanley lowered their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. Finally, UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,477 shares of company stock valued at $5,102,643 over the last three months. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the business. Voloridge Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $77,587,000. Qube Research & Technologies Ltd acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $51,295,000. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the last quarter. Royal London Asset Management Ltd. raised its position in Halozyme Therapeutics by 122.3% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock valued at $57,321,000 after purchasing an additional 606,236 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Halozyme Therapeutics by 155.7% in the third quarter. AQR Capital Management LLC now owns 968,511 shares of the biopharmaceutical company’s stock worth $71,031,000 after purchasing an additional 589,711 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q2 results significantly exceeded expectations: Revenue rose 48% year over year to $481 million, versus the $402.28 million analyst consensus, while adjusted EPS of $2.28 surpassed estimates of $1.79 and increased from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth underscores the strength of Halozyme’s platform: Royalty revenue increased 50% year over year to $308 million. Management highlighted the repeatability, scalability, diversification and durability of the ENHANZE drug-delivery platform. Halozyme Q2 2026 Earnings Call Transcript
• Positive Sentiment: Full-year 2026 guidance was raised: Halozyme now expects revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is above the approximately $8.02 consensus estimate. Halozyme 2026 Guidance Update
• Positive Sentiment: Business development momentum improved: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year target of three. The agreements potentially broaden future revenue and royalty opportunities. Halozyme Collaboration Agreements
• Neutral Sentiment: The strong results raise expectations for continued execution; investors will likely focus on whether new collaborations translate into durable commercial royalties and whether Halozyme can sustain its elevated growth rates.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.